Fig. 9.1
An ultrasound of a small testicular mass ideally considered for organ sparing being located at the lower pole and palpable: (a) microcalcifications throughout the testis (b) small hypi-echoic area suspicious for a focus of cancer
Horstman et al. reported their experience with nine incidental nonpalpable testicular lesions in approximately 1,600 scrotal US done for other indications. Seventy-eight percent of lesions were benign and 55% were less than 1 cm. The authors concluded that incidentally discovered lesions are likely to be benign and these patients should undergo initial excisional biopsy through an inguinal approach before proceeding to radical orchiectomy [13]. Conversely, other authors caution that impalpable lesions of the testis may be malignant [63, 64]. Furthermore, nonpalpable testicular embryonal carcinoma as well as mature teratoma has been recently reported [65, 66].
Evidence of testicular microlithiasis on US was previously thought to be a risk factor for malignancy but is now known to occur in approx 5% of healthy asymptomatic men. In fact, 98.4% of men with testicular microlithiasis will not go on to develop malignancy [67]. Testicular microlithiasis is an uncommon condition in which many small nonshadowing hyperechoic foci of 1–3 mm are apparent within the testicular parenchyma, representing calcium deposits in the lumina of seminiferous tubules (Fig. 9.1). Criteria for diagnosis is the presence of ≥5 foci per US transducer field. Microlithiasis has been associated with various conditions, including Kleinfelter’s syndrome, cryptorchidism, Down’s syndrome, male pseudohermaphroditism, pulmonary alveolar microlithiasis, and testicular cancer [68]. Testicular microlithiasis is found in about 50% of men with GCTs so the presence of a mass and microlithiasis suggests malignancy [69].
MRI as an imaging tool for the testis is developing but is unlikely to replace US, particularly as a first line investigation [70]. It can provide additional useful information in patients with equivocal US findings. MRI can be of value when the location of a scrotal mass is uncertain or when there is difficulty in differentiating an inflammatory or vascular abnormality from a solid testicular mass [71]. Normal testis appears homogeneous with intermediate signal intensity on T1-weighted images and high signal intensity on T2-weighted images relative to skeletal muscle. The epididymis has signal intensity characteristics similar to normal testicular parenchyma on T1-weighted images but lower signal intensity on T2-weighed images. Solid intratesticular lesions have lower signal intensity on T2-weighted images, in excellent contrast to the background high signal intensity of testicular parenchyma. At MRI, seminomas are usually homogeneous in appearance, isointense to normal testicular parenchyma on T1-weighted images and hypointense on T2-weighted images, although MRI does not allow a reliable histological diagnosis of testicular cancer subtypes. Nonseminomas, typically more heterogeneous, are usually iso- to hyperintense compared with normal testicular parenchyma on T1-weighted images, and hypointense on T2-weighted images [62].
A few nonmalignant lesions can be indistinguishable from testicular cancer, for which surgical exploration is often required. An example can be focal subacute or chronic orchitis, which can persist for months or years.
Biopsy of Testicular Lesions
Peroperative, percutaneous needle biopsy of testicular masses is not routinely recommended [11, 72]. In a meta-analysis, scrotal violation increased the risk of local recurrence from 0.4 to 2.9% [73]. The overall survival was not reduced when patients were followed with appropriate surgical management and close observation [74].
Due to concerns about seeding, excisional biopsy with FSE is more commonly undertaken as part of an organ-sparing approach. For those lesions confirmed to be benign by FSE, the remnant testis may be returned to the scrotum. If a GCT is found, CIS will occasionally be picked up on frozen section but this should not be relied upon. The concern with FSE has been misinterpretation of the mass or missing of CIS in the surrounding “normal” parenchyma when comparing to permanent sectioning and this should be discussed with patients [66, 75]. The detection of CIS is suboptimal not only because of pathological interpretation but also skip lesions amongst normal parenchyma. A FSE is generally felt to be inadequate [76]. The detection of CIS using immunohistochemistry with placental alkaline phosphatase (PLAP) is not straightforward but requires permanent section [77]. Consideration of adjuvant radiation observation or radical orchiectomy may be discussed with the patient postoperatively once the permanent sections have been examined for CIS and the GCT type determined(see below). The final stage of the primary tumor will also dictate what if any adjuvant treatment is required.
The main objective of the FSE is to confirm a GCT and confirm the lesion has a margin of normal testicular parenchyma. Some groups advocate multiple core biopsies of each sidewall and from the bottom of the tumor bed after the tumor has been excised while others (including our institution) rely on examination of the edge of the mass [78]. For detecting GCT, FSE has found to be 100% accurate for the presence of tumor in the largest study of 354 patients where there were 317 malignant patients and 37 benign patients when compared to the definitive histology [79]. A small (8%) error rate in differentiating seminoma from nonseminoma occurred in this study with no clinical consequences. A smaller study of around 30 patients also had 100% accuracy for malignancy [80]. We would suggest that equivocal results do occur and that a figure around 98% in the hands of an experienced uropathologist is probably more accurate [59].
Informed consent is a very important part of the patient evaluation and assessment for PO. The organ preserving approach is not yet established for primary GCT management, so a surgeon should very carefully select the patients after evaluating their psycho emotional status. Every patient should be informed and consented for the possibility of total testicular removal if the decision to extend the procedure is made intraoperatively or reoperation for completion orchiectomy is recommended.
Treatment
Partial Orchiectomy: Technique
PO is usually performed under general anesthesia with the patient in the supine position. In the usual sterile manner including prepping the scrotum, a 4–5 cm incision is made along the Langerhans skin line about 2 cm above and parallel to the inguinal ligament. The initial steps are the same as radical orchiectomy. The subcutaneous fat is dissected to expose Scarpa’s fascia which is incised to the level of the external oblique aponeurosis which in turn is incised towards the internal inguinal ring. The ileoinguinal nerve is identified, dissected free of the cord and preserved after identification. The cord is clamped with a rubber-shod clamp or Penrose tourniquet at the level of internal ring and the testicle is delivered from the scrotum into the wound, taking care to control small vessels. The gubernaculum attachments are divided with electrocautery or ligated. Before opening tunica vaginalis, the lesion is located in the testicle by palpation or with the help of the intraoperative US [75] (Fig. 9.2). Warm or cold ischemia remains controversial but if performed, Steiner and colleagues advocate immersion of the testis in crushed ice or slush for 5 min before spermatic cord occlusion [78, 81]. If FSE is planned, the wound should be covered before opening the tunica vaginalis and incising the parenchyma. An operating microscope with 6–25× magnification can be used to help identification of testis and tumor blood supply [75]. The tumor is enucleated with an attempt to preserve surrounding normal parenchyma. There are possible two scenarios after the result of the FSE. If the lesion appears to be benign, the vessels are unclamped and after ensuring hemostasis, the tunica albuginea is closed with running 4-0 or 5-0 absorbable suture. When the FSE is positive for malignancy and a decision is made to proceed with PO, some authors recommended multiple biopsies of the remaining tumor bed to rule out other possible malignant lesions or CIS [33]. Testicle is placed back in the scrotum without twisting or tension. After returning the testis to the scrotum, the external oblique aponeurosis is closed in a running fashion with absorbable sutures after thorough hemostasis. Scarpas’ fascia is also closed with absorbable sutures. Skin is closed with 4-0 subcuticular sutures. Compressive scrotal support can minimize wound edema. The patient usually goes home the same day or may stay overnight.
Fig. 9.2
Partial orchiectomy. After testis delivered through the inguinal incision (a), Penrose drain used for vascular control and incision is made of tunica albuginea (b), tumor is incised with up to 5 mm margin of normal testicular parenchyma (c). Tunica albuginea is repaired with absorbable sutures (d). Printed with permission of Nature Publishing Group. Alvaro Zuniga, Nathan Lawrentschuk and Michael A. S. Jewett. Organ-sparing approaches for testicular masses. Vol 7, Dec 31, 1969
Radiation
The well-known radiosensitivity of semonimas prompted several studies of treatment of primary GCT with radiation without PO [82, 83]. However, the required dose of radiation can affect hormone production and replacement therapy may be necessary. Previous studies showed that 33 Gy decrease testosterone levels in 50% of men [84]. At lower doses for CIS, there is a decline in testosterone production and 40% of men require required testosterone replacement [84, 85]. The high risk of testosterone replacement supports a surgical approach, but in selected cases radiation can be successfully used [82, 83]. Further dose-fractionation studies needed to optimize protocol of tumor eradication with acceptable hormone function preservation.
Chemotherapy
There is only one report of chemotherapy alone in the organ-sparing treatment of testicular cancer. Tomita et al. reported bilateral GCT where the unilateral testis was preserved by three courses of BEP chemotherapy [86]. Patients showed no recurrence and testicular preservation between 24 and 82 months after treatment. On the other hand the effect of chemotherapy in eradicating CIS is very controversial, so further studies with larger number of patients and longer follow-up needed to recommend chemotherapy as safe organ-sparing approach.
Ablative Therapy with High-Intensity Focused Ultrasound (HIFU)
HIFU is a minimally invasive technique to achieve coagulation necrosis of the tumor (90–100 °C). It has been successfully used in other applications in oncology, particularly for treatment of patients with rectal, prostate, breast, liver, and pancreatic tumors [87–93]. Therapeutic goal for HIFU in GCT is similar to that of local tumor excision in patients selected for organ-preservation strategy. The group from Germany have published their experience with GCT in seven patients with a solitary testis and mean follow-up of 42 months [94]. Transscrotal HIFU under general anesthesia with mean operative time of 31 min, followed 6 weeks later by prophylactic testicular irradiation (18–20 Gy). One patient received two cycles of chemotherapy for a single suspicious retroperitoneal lymph node diagnosed 6 months after HIFU. Other six patients remained tumor free at the mean follow-up of 42 (3–93) months. One patient who refused adjuvant radiation developed a recurrent tumor within 6 months was treated with radical orchiectomy. HIFU is a very promising treatment, producing necrosis without surgical trauma to the vascular anatomy and allows to preserve more gonadal function. But the downside of this would be lack of histological examination of the lesion.
Carcinoma In Situ Considerations
CIS is a malignant preinvasive testicular GCT [28, 33]. It is common in the nontumor part of the testis containing GCT and also seen in 5% of the contralateral testes. The cumulative probability for testicular tumor development in patients with CIS has been reported to be 50–70% after 5–7 years in Scandinavia [33, 95]. CIS has been reported to be significantly associated with poor spermatogenesis and with testicular atrophy, representing potentially impaired fertility [96]. The diagnosis of CIS at the time of PO or on permanent sections after the organ preserving procedure is challenging. Radiotherapy, chemotherapy, or surveillance are alternatives to completion radical orchiectomy [10, 97, 98].
Radiation treatment is commonly recommended, particularly in Europe. A total dose of 20 Gy (single doses of 2 Gy, five fractions per week) is recommended in the EAU guidelines [99]. Several groups have reported the results of adjuvant radiation after PO. The German Testicular Cancer Group did not observe local recurrence in 46 patients treated with adjuvant radiation but only 4 of 26 patients who did not receive radiation therapy had local recurrence [28]. This may compromise androgen production in up to 25% of men [100]. Lower doses, <20 Gy, were reported to have a variable impact on testosterone production but better preservation of Leydig cell function [10, 28, 84, 97, 100–104]. However, dose reduction may result in lower rates of complete CIS eradication. Radiotherapy may also destroy potential residual fertility, so it may be postponed in those who wish to father children as long as close surveillance is practiced [28]. The time between diagnosis of CIS and the development of a testicular tumor is usually long. This strategy was proposed by Heidenreich et al. who reported ten patients with concomitant CIS who postponed radiotherapy to father a child [28]. Five were successful with spontaneous pregnancy and five required vitro fertilization. Where radiation is undertaken, regular determination of the serum testosterone levels should be performed [97]. In case of clinical signs of androgen deficiency or subnormal testosterone levels hormone supplementation should be initiated.
Chemotherapy, particularly cisplatin-based has been reported to have some effect on CIS but the response can be variable because the cumulative risk of recurrent CIS at 10 years is 42% [105]. More recent publication from Kleinschmidt et al. reported a limited place for chemotherapy in CIS with a 63% failure rate on rebiopsy at 9 months post treatment [106].
Surveillance is the option that is frequently recommended, particularly in North America, for men who will be compliant with scheduled follow-up. Follow-up includes regular physician visits with scrotal US at yearly intervals.
Summary
Patients with palpable and nonpalpable testicular lesions may have benign rather than malignant tumors. The organ-sparing approach with partial orchiectomy is an option to preserve testicular function. The role for PO is less well established for malignant tumors but can be safely performed for solitary tumors, <2 cm in diameter when the blood supply to the remaining testis can be preserved. Residual androgen and fertility function is usually worth the risk of recurrence, which is low. Careful monitoring of the residual testis is required. The presence of CIS in the testis can complicate further management but adjuvant radiation is effective and can be delayed to allow for fertility.
References
1.
2.
3.
Society AC. Cancer facts and figures 2011. Atlanta: American Cancer Society; 2011.
4.
5.
6.
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15:594–603.
7.
8.
9.
10.
11.
12.
Richie J. Simultaneous bilateral tumors with unorthodox management. World J Urol. 1984;2:74–5.
13.
Horstman WG, Haluszka MM, Burkhard TK. Management of testicular masses incidentally discovered by ultrasound. J Urol. 1994;151:1263–5.PubMed
14.
Haas GP, Shumaker BP, Cerny JC. The high incidence of benign testicular tumors. J Urol. 1986;136:1219–20.PubMed
15.
Kressel K, Schnell D, Thon WF, Heymer B, Hartmann M, Altwein JE. Benign testicular tumors: a case for testis preservation? Eur Urol. 1988;15:200–4.PubMed
16.
17.
Carmignani L, Morabito A, Gadda F, Bozzini G, Rocco F, Colpi GM. Prognostic parameters in adult impalpable ultrasonographic lesions of the testicle. J Urol. 2005;174:1035–8.PubMedCrossRef